Comments
Jubilant Life Sciences has posted a contracted net profit for the first quarter ended June 30, 2017.
The pharmaceutical firm’s net profit for the three-month period dipped by over 12 per cent at ₹143.71 crore, against ₹163.92 crore during the same quarter of the previous fiscal.
However, the company’s total income saw a nearly 10 per cent jump during the June quarter at ₹1,602.86 crore compared with the same period of the previous fiscal.
“The integration of Triad acquisition is expected to give benefit of a niche specialty injectable portfolio with additional revenues of about $200 million,” the company said in a statement on Tuesday.
In a joint statement, Chairman Shyam S Bhartia and Co-Chairman & Managing Director Hari S Bhartia, said the company had witnessed a contraction in margins in its US generics business.
The company’s scrip closed at ₹703.70, down 1.17 per cent on Tuesday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.